LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Publisher: American Chemical Society
Languages: English
Types: Article
Subjects:
A series of dibasic des-hydroxy β2 receptor agonists has been prepared and evaluated for potential as inhaled ultra-long acting bronchodilators. Determination of activities at the human β-adrenoreceptors demonstrated a series of highly potent and selective β2 receptor agonists that were progressed to further study in a guinea pig histamine-induced bronchoconstriction model. Following further assessment by; onset studies in guinea pig tracheal rings and human bronchial rings contracted with methacholine (guinea pigs) or carbachol (humans), duration of action studies in guinea pigs after intratracheal (i. t.) administration and further selectivity and safety profiling AZD3199 was shown to have an excellent over all profile and was progressed into clinical evaluation as a new ultra-long acting inhaled β2 receptor agonist with rapid onset of action.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Long-acting beta-Agonists and their association with Inhaled corticosteroids in COPD. Curr. Med. Chem. 2013, 20, 1477-1495.
    • 2. Walker, J. K. L.; Penn, R. B.; Hanania, N. A.; Dickey, B. F.; Bond. R. A. New perspectives regarding β(2)-adrenoceptor ligands in the treatment of asthma. Br. J. Pharm. 2011, 163 18-28.
    • 3. Cazzola, M; Page, C. P.; Rogliani, P.; Matera, M. G. 2- agonist therapy in lung disease. Amer. J. Resp. and Critical Care Medicine 2013, 187, 690-696.
    • 4. Matera M. G.; Cazzola M. Ultra-long-acting beta2- adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? Drugs 2007, 67, 503-515.
    • 5. Bouyssou, T.; Hoenke, C.; Rudolf, K.; Lustenberger, P.; Pestel, S.; Sieger, P.; Lotz, R.; Heine, C.; Buettner, F. H.; Schnapp, A.; Konetzki, I. Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24 h bronchodilatory efficacy Bioorg. Med. Chem. Lett. 2010, 20, 1410-1414.
    • 6. Procopiou, P. A.; Barrett, V. J.; Bevan, N. J.; Biggadike, K.; Box, P. C.; Butchers, P. R.; Coe, D. M.; Conroy, R.; Emmons, A.; Ford, A. J.; Holmes, D. S.; Horsley, H.; Kerr,F.; Li-KwaiCheung, A-M.; Looker, B. E.; Mann, I. S.; McLay, I. M.; Morrison, V. S.; Mutch, P. J.; Smith, C. E.; Tomlin, P. Synthesis and structure-activity relationships of long-acting β2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J. Med. Chem. 2010, 53, 4522- 4530.
    • 7. Davies, S. L.; Castaner, J. Indacaterol Drugs of the Future, 2005, 30, 1219-1224.
    • 8. Roig, J.; Hernando, R.; Mora, R. Open. Resp. Med. J., 2009, 3, 27-30.
    • 9. Baur, F.; Beattie, D.; Beer, D.; Bentley, D.; Bradley, M.; Bruce, I.; Charlton, S. J.; Cuenoud, B.; Ernst, R.; Fairhurst, R. A.; Faller, B.; Farr, D.; Keller, T.; Fozard, J. R.; Fullerton, J.; Garman, S.; Hatto, J.; Hayden, C.; He, H.; Howes, C.; Janus, D.; Jiang, Z.; Lewis, C.; Loeuillet-Ritzler, F.; Moser, H.; Reilly, J.; Steward, A.; Sykes, D.; Tedaldi, L.; Trifilieff, A.; Tweed, M.; Watson, S.; Wissler, E.; Wyss, D. The identification of indacaterol as an ultralong-acting inhaled β2-adrenoceptor agonist J. Med. Chem. 2010, 53, 3675-3684.
    • 10. Mortimer, K. J.; Harrison, T. W.; Tang, Y.; Wu, K.; Lewis, S.; Sahasranaman, S.; Hochhaus, G.; Tattersfield, A. E. Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. Br. J. Clin. Pharm. 2006, 62, 412- 419.
    • 11. Anderson, G. P.; Lindén, A.; Rabe, K. F. Why are long-acting beta-adrenoceptor agonists long-acting? Eur. Respir. J. 1994, 7, 569-578.
    • 12. Green, S. A,; Spasoff, A. P.; Coleman, R. A.; Johnson M.; Liggett, S. B. Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor. J Biol Chem. 1996, 39, 24029-24035.
    • 13. Bao, Y.; Horst, L. Action mechanism of long-acting bronchodilators. Acta Pharm. Sinic. 1998, 20, 191-196.
    • 14. Deyrup, M. D.; Nowicki, S. T.; Richards, N. G. J.; Otero, D. H.; Harrsison, J. K.; Baker, S. P. Structure-affinity profile of 8-hydroxycarbostyril-based agonists that dissociate slowly from the beta2-adrenoceptor. Arch. Pharmacol. 1999, 359, 168-177.
    • 15. Patton, J. S.; Byron, P. R. Inhaling medicines: delivering drugs to the body through the lungs. Nature Rev. Drug Discovery 2007, 6, 67-74.
    • 16. Cooper, A. E.; Ferguson, D.; Grime, K. Optimization of DMPK by the inhaled route: challenges and approaches. Current Drug. Met. 2012, 13, 457-473.
    • 17. Alikhani, V.; Beer, D.; Bentley, D.; Bruce, I.; Cuenoud, B. M.; Fairhurst, R. A.; Gedeck, P.; Haberthuer, S.; Hayden, C.; Janus, D.; Jordan, L.; Lewis, C.; Smithies, K.; Wissler, E. Longchain formoterol analogues: an investigation into the effect of increasing amino-substituent chain length on the β2- adrenoceptor activity. Bioorg. Med. Chem. Lett. 2004, 14, 4705-4710.
    • 18. White, M. V.; Sander, N. Asthma from the perspective of the patient. J. Allergy Clin. Immunol. 1999, 104, s47-52.
    • 19. Kuna P.; Ivanov Y.; Trofimov, V. I.; Saito, T.; Beckman, O.; Bengtsson, T.; Jorup, C.; Maltais, F. Efficacy and safety of AZD3199 vs formoterol in COPD: a randomized, doubleblind study. Resp. Research. 2013, 14, 64.
    • 20. Stocks, M. J.; Alcaraz L.; Bailey A.; Bonnert, R.; Cadogan, E.; Christie J.; Connolly, S.; Cook A.; Fisher A.; Flaherty A.; Hill, S.; Humphries A.; Ingall A.; Jordan S.; Lawson M.; Mullen A.; Nicholls D; Paine S.; Pairaudeau G.; St-Gallay S.; Young A. Design driven HtL: The discovery and synthesis of new high efficacy β₂-agonists. Bioorg. Med. Chem. Lett. 2011, 21, 4027- 4031.
    • 21. Austin, R. P.; Barton, P.; Bonnert, R. V.; Brown, R. C.; Cage, P. A.; Cheshire, D. R.; Davis, A. M.; Dougall, I. G.; Ince, F.; Pairaudeau, G.; Young, QSAR and the rational design of long-acting dual D2 -receptor/2-adrenoceptor agonists. J. Med. Chem. 2003, 46, 3210-3220.
    • 22. Alcaraz, L.; Bailey, A.; Cadogan, E.; Connolly, S.; Jewell, R.; Jordan, S.; Kindon, N.; Lister, A.; Lawson, M.; Mullen, A.; Dainty I.; Nicholls, D.; Paine, S.; Pairaudeau G.; Stocks, M. J.; Thorne, P.; Alan Young, A. From libraries to candidate: the discovery of new ultra long-acting dibasic β₂- adrenoceptor agonists. Bioorg. Med. Chem. Lett. 2012, 22, 689-695.
    • 23. Procopiou, P. A.; Barrett,V. J.; Biggadike, K.; Butchers, P. R.; Craven, A.; Ford, A. J.; Guntrip,S. B.; Holmes,D. S.; Hughes, S. C.; Jones, A. E.; Looker, B. E.; Mutch, P. J.; Ruston, M.; NeedhamD.; Smith C. E. Discovery of a rapidly metabolized, long-acting β2 adrenergic receptor agonist with a short onset time incorporating a sulfone group suitable for once-daily dosing. J. Med. Chem. 2014, 57, 159−170.
    • 24. Walland, A.; Palluk, R.; Burkard, S.; Hammer, R. Compensation of muscarinic bronchial effects of talsaclidine by concomitant sympathetic activation in guinea pigs. Eur.J. Pharmacol. 1997, 330, 213-219.
    • 25. Connolly, S.; Alcaraz, L.; Bailey, A.; Cadogan, E.; Christie, J.; Cook, A. R.; Fisher, A. J.; Hill, S.; Humphries, A.; Ingall, A. H.; Kane, Z.; Paine, S.; Pairaudeau, G.; Stocks, M. J.; Young, A. Design-driven LO: the discovery of new ultra long acting dibasic β2-adrenoceptor agonists. Bioorg. Med. Chem. Lett. 2011, 21, 4612-4616.
    • 26. Tayab, Z. R.; Hochhaus, G. Pharmacokinetic/pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems. Expert. Opin. Drug. Deliv. 2005, 2, 519-532.
    • 27. Bailey, A.; Bonnert, R.; Flaherty, A.; Pairaudeau, G.; Stocks, M. 2007, WO 2007027133.
    • 28. Giles, M. E.; Thomson, C.; Eyley, S. C.; Cole, A. J.; Goodwin, C. J.; Hurved, P. A.; Morlin, A.J. G.; Tornos, J.; Atkinson, S.; Just, C.; Dean, J. C.; Singleton, J. T.; Longton, A. J.; Woodland, I.; Teasdale, A.; Gregertsen, B.; Else, H.; Athwal, M. S.; Tatterton, S.; Knott, J. M.; Thompson, N.; Smith, S. Development of a manufacturing process for Sibenadet hydrochloride, the active ingredient of Viozan. J. Org. Process Res. Dev. 2004, 8, 628-642.
  • No related research data.
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Cite this article